OraSure Technologies, Inc.
- Open
- 4.50
- Day high
- 4.51
- Day low
- 4.31
- Prev close
- 4.50
- Volume
- 554K
- Mkt cap
- $307M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.0
- P/S
- 2.7
- Yield
- —
- Per share
- —
- ▲Insiders net buying $75K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions mixed (13F)
OraSure Technologies, Inc. (OSUR) is a Healthcare company listed on NASDAQ. The stock is up 50% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4).
OraSure Technologies, Inc. (OSUR) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
OSUR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-0.23 | $-0.32 | -39.1% | $28M | +0.8% |
| Feb 25, 2026 | $-0.17 | $-0.19 | -11.8% | $-88M | -416.2% |
| Nov 5, 2025 | $-0.16 | $-0.13 | +18.8% | $27M | +2.4% |
| May 7, 2025 | $-0.15 | $-0.18 | -20.0% | $934000 | -96.8% |
| May 8, 2024 | $-0.01 | $0.04 | +766.7% | $54M | +3.9% |
| Feb 27, 2024 | $0.09 | $0.27 | +200.0% | $76M | +2.4% |
| Aug 3, 2023 | $-0.06 | $-0.07 | -16.7% | $85M | +74.7% |
| May 10, 2023 | $0.14 | $0.37 | +164.3% | $155M | +22.4% |
| Feb 14, 2023 | $0.01 | $0.21 | +2200.1% | $123M | +26.8% |
| Feb 23, 2022 | $-0.16 | $-0.14 | +12.5% | $64M | +2.6% |
| Nov 3, 2021 | $-0.05 | $-0.21 | -320.0% | $54M | +15.8% |
| May 5, 2021 | $0.04 | $0.05 | +12.9% | $59M | +2.8% |
OSUR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 5, 2026 | Bertrand John D.director | Grant | 46,106 | — |
| Jun 5, 2026 | Boyd Steven Kyledirector | Grant | 46,106 | — |
| Jun 5, 2026 | Gagliano Nancy Jdirector | Grant | 46,106 | — |
| Jun 5, 2026 | Marmora Leliodirector | Grant | 46,106 | — |
| Jun 5, 2026 | Kenny John P.director | Grant | 46,106 | — |
| Jun 5, 2026 | McMahon Robert W.director | Grant | 46,106 | — |
| May 14, 2026 | McMahon Robert W.director | Tax | 22,888 | $3.02 |
| May 14, 2026 | Boyd Steven Kyledirector | Buy | 25,000 | $2.98 |
| May 14, 2026 | Marmora Leliodirector | Tax | 28,406 | $3.02 |
| May 14, 2026 | Gagliano Nancy Jdirector | Tax | 21,305 | $3.02 |
| May 14, 2026 | Bertrand John D.director | Grant | 33,661 | — |
| Mar 30, 2026 | Boyd Steven Kyledirector | Grant | 5,246 | $3.10 |
| Mar 30, 2026 | Boyd Steven Kyledirector | Tax | 1,416 | $3.10 |
| Mar 23, 2026 | McGrath Kenneth Jofficer: Chief Financial Officer | Buy | 32,300 | $2.93 |
| Mar 23, 2026 | EGLINTON MANNER CARRIEdirector, officer: President & CEO | Buy | 32,300 | $2.93 |
Source: OSUR SEC Form 4 filings, latest Jun 5, 2026. For informational purposes only — not investment advice.
See the full OSUR insider & 13F page →OraSure Technologies, Inc. company profile
Overview
OraSure Technologies, Inc. (NASDAQ:OSUR) is a medical device company founded in 2000 and headquartered in Bethlehem, Pennsylvania. The company specializes in developing, manufacturing, and marketing oral fluid diagnostic products and specimen collection devices. Since going public in 1986, OraSure has established itself as a leader in non-invasive diagnostic testing, particularly in HIV testing and sample collection technologies. The company operates globally, serving markets in the United States, Europe, and internationally through two primary business segments: Diagnostics and Molecular Solutions.
Business
OraSure Technologies operates in the medical diagnostics industry, focusing on oral fluid-based testing and specimen collection devices. The company's approach centers on non-invasive diagnostic solutions that use saliva, urine, and other bodily fluids instead of traditional blood draws, making testing more accessible and comfortable for patients. The company operates through two main business segments. The Diagnostics segment generates approximately 60-65% of core revenue and includes rapid diagnostic tests such as the OraQuick HIV self-test (the first FDA-approved at-home HIV test), OraQuick hepatitis C test, and COVID-19 rapid tests under the InteliSwab brand. These tests provide results in minutes and can be used in clinical settings or at home, addressing critical public health needs in HIV prevention, hepatitis screening, and pandemic response. The Sample Management Solutions segment accounts for roughly 35-40% of core revenue and focuses on collection devices and laboratory services. This includes the Oragene and ORAcollect product lines for genetic material collection, microbiome collection products, and genomics laboratory services under the GenoFIND brand. These products enable researchers, healthcare providers, and direct-to-consumer genetic testing companies to collect, stabilize, and transport biological samples for various applications including ancestry testing, disease risk assessment, and pharmaceutical research. The company also developed specialized collection devices like the Colli-Pee for volumetric urine collection and various products for COVID-19 molecular testing. OraSure's products serve diverse markets including clinical laboratories, hospitals, public health organizations, government agencies, and commercial entities involved in genetic testing and research.
Revenue model
OraSure generates revenue through product sales of diagnostic tests and collection devices to various customer segments. The company's business model relies on manufacturing and selling consumable diagnostic products that require repeat purchases, creating recurring revenue streams. The primary revenue sources include direct sales of rapid diagnostic tests to healthcare providers, government agencies, and international public health organizations. For HIV testing, major customers include PEPFAR (President's Emergency Plan for AIDS Relief), WHO-affiliated programs, and domestic healthcare systems. The Sample Management Solutions segment generates revenue by selling collection kits to genetic testing companies, pharmaceutical researchers, and academic institutions, often through multi-year supply agreements. Several factors influence OraSure's margins and profitability. Positive margin drivers include the company's proprietary technology platform that commands premium pricing, economies of scale in manufacturing, and the recurring nature of consumable products. International sales, particularly to government-funded health programs, often provide stable, high-volume orders. The company's move to insource manufacturing also improves cost control and margins. Negative margin pressures come from competitive pricing in commodity-like testing markets, regulatory compliance costs, and research and development investments required to maintain technological leadership. The company faces uncertainty from government funding changes, particularly PEPFAR budget allocations that affect HIV testing demand. Additionally, the consumer genomics market softness has impacted Sample Management Solutions revenue, and the company must navigate potential tariff impacts on imported components, though it has been proactively reshoring manufacturing to mitigate this risk.
Competitive moat
OraSure's competitive moat is moderate but specialized, built primarily around its expertise in oral fluid diagnostics and regulatory approvals rather than insurmountable barriers. The company's strongest defensive position lies in its FDA approvals and WHO prequalifications for critical diagnostic tests, particularly the OraQuick HIV self-test which was the first FDA-approved at-home HIV test. These regulatory approvals create significant barriers for competitors and provide multi-year exclusivity periods. The company has developed proprietary collection and testing technologies that offer advantages in ease of use, accuracy, and patient comfort compared to traditional blood-based tests. Its long-standing relationships with international health organizations, government agencies, and public health programs create switching costs and preferred vendor status that competitors find difficult to replicate. However, OraSure's moat faces several challenges. The diagnostic testing market is highly competitive with well-funded players like Abbott, Roche, and other major medical device companies that have greater resources for R&D and market penetration. The company's dependence on government funding programs creates vulnerability to policy changes and budget cuts. Additionally, technological advances in molecular diagnostics and point-of-care testing could potentially disrupt OraSure's oral fluid-based approach. The recent acquisition of Sherlock Biosciences represents an attempt to strengthen the moat by adding molecular diagnostic capabilities, but this expansion into new technology areas also increases execution risk. Overall, while OraSure has carved out a defensible niche in oral fluid diagnostics, its moat is not exceptionally wide and requires continuous innovation and regulatory success to maintain competitive advantages.
Risks & safety
OraSure demonstrates a strong financial safety profile with substantial cash reserves and minimal debt, though operational losses create ongoing cash burn concerns. • Liquidity and Solvency: $248 million in cash and short-term investments with only $22 million in total debt, providing exceptional liquidity cushion. Current ratio of 12.3x indicates very strong short-term financial stability. • Cash Flow: Q1 2025 operating cash flow of -$19.7 million and free cash flow of -$20.2 million indicate continued cash burn, though this improved from previous periods. Full year 2024 generated positive $27.4 million operating cash flow. • Valuation Metrics: Trading at 0.64x book value and negative P/E due to losses. Graham net-net ratio of 2.94 suggests potential deep value opportunity. EV/EBITDA is negative due to negative EBITDA. • Debt Management: Debt-to-equity ratio of only 3.6% indicates minimal leverage risk. Company maintains zero net debt position. • Other Considerations: Revenue volatility from government contract timing and COVID-related sales creates earnings unpredictability. Recent Sherlock Biosciences acquisition will require $20-25 million investment over coming years, adding to cash burn in near term.
Recent development
Over the past few years, OraSure has undergone significant strategic transformation focused on three pillars: strengthening its foundation, elevating core growth, and accelerating profitable growth. The company has consolidated operations by reducing its workforce by 11%, targeting over $15 million in annual cost savings, and streamlining its operational footprint through facility consolidation and manufacturing insourcing. The most significant recent development was the acquisition of Sherlock Biosciences to expand into molecular diagnostics, particularly for developing a chlamydia and gonorrhea (CT/NG) molecular self-test. This represents a major technological expansion beyond OraSure's traditional oral fluid rapid testing expertise. The company is investing $20-25 million primarily in clinical trials for FDA approval of the CT/NG product. OraSure has also expanded its product portfolio through strategic partnerships and new product launches. Key developments include securing WHO prequalification for its hepatitis C self-test, the first such approval globally, and receiving FDA approval to expand the age range for its OraQuick HIV self-test. The company launched new products including the Syphilis Health Check and is developing blood proteomics solutions and the Colli-Pee urine collection device. Strategic partnerships have become increasingly important, including collaborations with Sapphiros for blood collection technologies, Diagnostics Direct for syphilis testing distribution, and PacBio for saliva collection devices. The company has also secured a BARDA contract for Marburg virus rapid antigen test development, demonstrating its capability in emerging infectious disease preparedness. OraSure is actively exiting non-core businesses, including winding down its Risk Assessment Testing segment and Diversigen Molecular Sequencing Services, to focus resources on higher-margin diagnostic and sample management opportunities. The company has also authorized a $40 million stock repurchase program, signaling confidence in its strategic direction.
OSUR company profile · for informational purposes only — not investment advice.
Track OSUR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free